Navigation Links
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
Date:1/6/2014

ng the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, development progress of the Company's companion diagnostics, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company's 10-Q filed with the Securities and Exchange Commission on October 23, 2013. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
2. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
3. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
6. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
7. Advanced Biofuels USA's Joanne Ivancic Recognized as One of Top 100 People in the BioEconomy by Biofuels Digest
8. Westchase Neck Injury Chiropractor is Now Offering the Newest Advanced Care Treatments for Injury and Chronic Pain, Courtesy of Elan Wellness Center
9. ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
10. New Ocean Sensing and Monitoring Brings Tutorial Approach to Latest Advances
11. Phoenix Research Labs Partners with Voxeleron to Advance Technology for Eye Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , PHILADELPHIA, Sept. 16 BioNanomatrix, Inc., a ... and personalized medicine, today announced that Dr. Charles Lee and ... Dr. Lee is a pioneer in the field of ... Medical School and the Broad Institute. Dr. Barker, the ...
... , , , ... Pervasis Therapeutics, Inc. today announced that it completed the ... financing. The proceeds will be used primarily to support ... biologically active therapy designed to reestablish healthy vasculature following ...
... DENVER, Colorado and JERUSALEM, September 16 ... Venture announced today,that Children,s Hospital is enrolling patients for ... series of cord blood transplant sites,worldwide, five of which ... Spain, Italy, Hungary and Israel. The trial is researching ...
Cached Biology Technology:BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... at the Johns Hopkins School of Medicine have discovered ... protein, critical for the development of spinal cord neurons. ... describes a never-before known mechanism of protein control. ... of chemical reaction control neuronal differentiation," says Shanthini Sockanathan, ...
... September 17th, 2009 / b3c newswire / - ... based on a 96 well plate. The System ... EMBL (European Molecular Biology Laboratory). , PROcellcare ... (in vitro) under the microscope with biological nutrient ...
... cells in the body could help scientists better understand how ... have found that the protein invadolysin, which is essential for ... parts of cells used to store fat. The study ... reduced amounts of fat deposits. The findings, published in ...
Cached Biology News:Antioxidant controls spinal cord development 2New Automatic cell feeding station PROcellcare for life cell imaging 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
... System is ideal for developing single and ... system contains the new, improved, and user ... user can design specific templates for commercial ... fully integrated graphing and data regression capabilities; ...
...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
Biology Products: